HepaRegeniX GmbH

Acute Liver Failure Pipeline Shows Promise with 5+ Therapies in Development Despite Recent Setbacks

- DelveInsight's 2025 pipeline analysis reveals over 5 companies developing novel therapies for acute-on-chronic liver failure, a condition with high mortality risk requiring urgent medical intervention. - GENFIT discontinued its VS-01 program for ACLF in September 2025 to focus on urea cycle disorders, while the FDA approved eGenesis's EGEN-5784 genetically engineered porcine liver for clinical trials. - HepaRegeniX's first-in-class MKK4 inhibitor HRX-215 demonstrated significant liver regeneration enhancement in preclinical models and showed safety in first-in-human trials. - The pipeline includes diverse therapeutic approaches spanning small molecules, albumin-based treatments, and regenerative therapies across various development stages from preclinical to Phase III.